U.S. News Room
August 01, 2024
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
Download
June 26, 2024
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
Download
June 02, 2024
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
Download